Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian G Goodfellow

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Nature|February 5, 2021
SARS-CoV-2 evolution during treatment of chronic infectionSteven A Kemp, Dami A Collier, Rawlings P Datir, et al.
Immunity|May 29, 2021
Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild diseaseLaura Bergamaschi, Federica Mescia, Lorinda Turner, et al.
Nature|December 23, 2021
Evolution of enhanced innate immune evasion by SARS-CoV-2Lucy G Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl, et al.
Scientific Reports|February 25, 2022
Improving the efficiency and effectiveness of an industrial SARS-CoV-2 diagnostic facilityJulie A Douthwaite, Christopher A Brown, John R Ferdinand, et al.
Nature Communications|December 15, 2020
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case reportMatthew S Buckland, James B Galloway, Caoimhe Nic Fhogartaigh, et al.
Nature|February 1, 2022
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicityBo Meng, Adam Abdullahi, Isabella A T M Ferreira, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Nature|February 5, 2021
SARS-CoV-2 evolution during treatment of chronic infectionSteven A Kemp, Dami A Collier, Rawlings P Datir, et al.
Immunity|May 29, 2021
Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild diseaseLaura Bergamaschi, Federica Mescia, Lorinda Turner, et al.
Nature|December 23, 2021
Evolution of enhanced innate immune evasion by SARS-CoV-2Lucy G Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl, et al.
Scientific Reports|February 25, 2022
Improving the efficiency and effectiveness of an industrial SARS-CoV-2 diagnostic facilityJulie A Douthwaite, Christopher A Brown, John R Ferdinand, et al.
Nature Communications|December 15, 2020
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case reportMatthew S Buckland, James B Galloway, Caoimhe Nic Fhogartaigh, et al.
Nature|February 1, 2022
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicityBo Meng, Adam Abdullahi, Isabella A T M Ferreira, et al.
Pageof 8